Opportunistic and other infections in HIV-infected children in latin America compared to a similar cohort in the United States

AIDS Research and Human Retroviruses

Volumn 28, Issue 3, 2012, Pages 282-288

  Alarcón, Jorge O ^a   Freimanis Hance, Laura ^b   Krauss, Margot ^b   Reyes, Mary F ^a   Cardoso, Claudete Aparecida Araújo ^c   Mussi Pinhata, Marisa M ^d   Cardoso, Edmundo ^e   Hazra, Rohan ^f  

^a Universidad Nacional Mayor de San Marcos   (Peru)

^b WESTAT   (United States)

^c HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ARTICLE; BACTERIAL PNEUMONIA; CHICKENPOX; CHILDHOOD DISEASE; COMPARATIVE STUDY; DERMATOPHYTOSIS; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SOUTH AMERICA; THRUSH; TUBERCULOSIS; UNITED STATES; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HERPESVIRIDAE INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; LATIN AMERICA; LONGITUDINAL STUDIES; MALE; MYCOSES; PROGNOSIS; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; TUBERCULOSIS; UNITED STATES;

EID: 84858136310     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0057     Document Type: Article

References (18)

1. Brady MT, Oleske JM, Williams PL, et al.: Pediatric AIDS Clinical Trials Group 219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010;53(1):86-94.
2. Gortmaker SL, Hughes M, Cervia J, et al.: Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345(21):1522-1528. (Pubitemid 33144917)
3. Gona P, Van Dyke RB, Williams PL, et al.: Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006;296:292-300. (Pubitemid 44079313)
4. Nesheim SR, Kapogiannis BG, Soe MM, et al.: Trends in opportunistic infections in the pre-and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007;120:100-109. (Pubitemid 47036246)
5. Chiappini E, Galli L, Tovo PA, et al.: Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007;21:1607-1615. (Pubitemid 47075482)
6. Candiani TM, Pinto J, Cardoso CA, et al.: Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica 2007;23(Suppl 3):S414-423.
7. Peña DA, Larrañaga LC, Luchsinger FV, et al.: Cytomega-lovirus disease in HIV-1 infected Chilean children. Rev Chil Infect 2007;24:477-484.
8. Martínez-Aguilar G, Vásquez de Kartzow R, Nava-Frias M, and Santos Preciado J: Infección por VIH en niños mex-icanos. Salud Públ México 1995;37:572-580.
9. Andino-Martinez K and Godoy-Mejia C: Pediatric AIDS: Opportunistic illnesses and recurrent infections. Rev Med Post UNAH 2001;6:50-54.
10. Hazra R, Stoszek SK, Freimanis-Hance L, et al.: NISDI Pediatric Study Group 2008. Cohort Profile: NICHD International Site Development Initiative (NISDI): A prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries. Int J Epidemiol 2009;38:1207-1214.
11. An SAS program for CDC Growth Charts Centers for Disease Control and Prevention (CDC) web site Available at www.cdc.gov/nccdphp/dnpa/growthcharts/ resources/sas.htm. Accessed October 22, 2008.
12. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, and Rogers MF: 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12);1-10. Preview/mmwrhtml/00032890.htm.
13. Rothman KJ: Modern Epidemiology. Little Brown and Company, Boston/Toronto, 1986.
14. Guillén S, Garćia ML, Resino S, et al.: Madrid Group for Research on Pediatric HIV Infection. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006). HIV Med 2010;11(4):245-252.
15. Mubiana-Mbewe M, Bolton-Moore C, Banda Y, et al.: Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia. Trop Med Int Health 2009;14:1190-1198.
16. Calder D and Qazi S: Evidence behind the WHO guidelines: Hospital care for children: What is the aetiology of pneumonia in HIV-infected children in developing countries? J Trop Pediatr 2009;55:219-224.
17. Levin MJ, Anderson JP, Seage GR 3rd, Williams PL, and the PACTG/IMPAACT 219C Team: Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr 2009;50:182-191.
18. Wood SM, Shah SS, Steenhoff AP, and Rutstein RM: Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008;121:e150-156.